first-in-class allosteric SHP2 phosphatase inh.

oral agent in multiple trials for cancer

from 1.5M cmpd biochemical HTS + SBDD

J. Med. Chem., Sep. 24, 2020

Novartis, Cambridge, MA

TNO155 is an allosteric inhibitor of the SHP2 phosphatase, which has been a hot target in oncology recently due to its promotion of mutant KRAS activity as well as its…


 become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

  • Stay up-to-date and save more time with exclusive members-only content
  • On-board new team members with educational content and case studies
  • Generate ideas and discussion with easy-to-read slide decks
  • Generate ideas and discussion with easy-to-read slide decks